Illumina Q3 - Good Partnerships

25-OCT-19

It's Jacaranda season in Joburg and earnings season in New York, as you can tell from our recent daily newsletters. Another of our main holdings in US portfolios is genetic sequencing machine maker Illumina, and they were also out with good third quarter results after the bell on Wall Street.


Read more...

23andMe using DNA to Develop New Drugs

19-AUG-19

Here is a positive story to get your week off to a good start. Genetic test-kit company 23andMe (which uses lots of our company Illumina's sequencing machines) is using those test results to develop new drugs.


Read more...

Illumina Q2 - Slower Growth

31-JUL-19

Gene sequencing giant Illumina reported its not so good second-quarter numbers. As we already new from a recent update, revenues fell short of management expectations as the company missed timelines for certain population genomic initiatives due to logistical issues. Leading to lower-than-expected direct-to-consumer sales.


Read more...

Illumina Growing Partnerships

20-JUN-19

Genetic sequencing machine maker Illumina has had a slow start as a Vestact recommended stock. It has fluctuated between $275 and $370 per share in recent months. The current price is $351.94.


Read more...

Illumina Q1 - Still Growing

29-APR-19

On Thursday night one of our new additions to the Vestact portfolio, Illumina, reported their Q1 numbers. In case you have forgotten, Illumina is the leading company producing gene sequencing machines.


Read more...

Illumina FY - Making Deals

01-FEB-19

Gene sequencing giant Illumina reported Q4 numbers on Tuesday after the market close. The San Diego, California based company reported record revenues of $867 million, up 11% year-on-year. For the year 2018, Illumina reported $3.3 billion of revenues, up 21% thanks to strong demand for sequencing and array systems, consumables and services.


Read more...

Illumina buys PacBio

08-NOV-18

Our most recent recommended stock addition is Illumina, the San Diego-based company that makes genetic sequencing machines. These are used to map out a person's DNA from a blood or saliva sample. In the process, patients (including unborn children) can determine their heritage, and the likelihood of contracting certain health conditions. There are also ongoing research projects to develop personalised genetic therapies, using the sequencing information gathered by these complex instruments. Read our original stock buy note here.


Read more...

Illumina Q3 numbers - strong beat

24-OCT-18

Illumina is the latest addition to our recommended stocks in the US. In case you forgot what they are all about, here is a refresher. Illumina develops, manufactures and markets integrated systems for the analysis of genetic variation and biological function.


Read more...

New Vestact US Recommended Stock - Buy Illumina

19-SEP-18

What's the next big thing for humanity? Think about it. What is big today? Googling, Netflix, Discovery Vitality points, Amazon, Parkruns, iPhones and Instagram. Twenty years ago, it was Coca-Cola, blue jeans, bank notes, Camel cigarettes and the Lion King. But what's next? What will be big in 10 years? time? That's where we want to get invested!


Read more...

Older stories...

Newsletter Sign Up

Sign up for our free daily market newsletter.

Paul Theron's Tweets

Byron Lotter's Tweets

Michael Treherne's Tweets

Bright Khumalo's Tweets